A newly revealed molecular tug-of-war may have implications for better understanding how a multitude of diseases and ...

The existing clinical data supporting safety and efficacy of CardiAMP Cell Therapy for HFrEF is subject to ongoing regulatory discussions in Japan and the United States. The compilation includes data ...

While the 21st century has been bumpy, it has also ushered in monumental scientific and technological breakthroughs that have ...

African Swine Fever Virus, ASFV, Viral Entry, Host Cell Invasion, CD163, Siglec-1, Macropinocytosis, Endosomal Escape, Immune Evasion, Signaling Pathways Share and Cite: Marcelino, K.B. and Fang, G.J.

The abstract will be published in the peer-reviewed Metabolism: Experimental and Clinical. The presentation will be available on Biomea Fusion's Investor Relations Page under the Events. Please find a ...

Biomea Fusion (BMEA) announced that it presented COVALENT-111 study results at the 23rd World Congress on Insulin Resistance, Diabetes & ...

SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that ...

Scientists demonstrated that glial fibrillary acidic protein (GFAP) promotes mitochondrial fission rather than blocking fusion. The genetic disorder Alexander disease is caused by mutations in the ...

South African mobile-network operator Cell C Holdings Ltd. opened flat in its debut on the Johannesburg Stock Exchange, with the continent’s top bourse on track for its best year for funds raised from ...

JOHANNESBURG, Nov 24 (Reuters) - South African mobile operator Cell C has raised about 2.7 billion rand ($156 million) through a share offer ahead of listing on the Johannesburg Stock Exchange (JSE) ...

Cell C is on track to debut on the JSE – which ITWeb understands will be next Thursday – as planned, despite a legal challenge of a 2024 approval of a change in majority ownership. The network ...